LLY

Business Context and Reporting Period

Company: Eli Lilly and Company (LLY)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Lilly operates as a single reportable segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. The company is a large accelerated filer.

Key Financial Metrics

Note: Total Debt includes short-term borrowings ($7,050 million) and long-term debt ($47,858 million) as of June 30, 2026.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 48% year-over-year for the quarter and 51% for the six-month period. Growth was driven primarily by volume increases in Mounjaro and Zepbound, partially offset by lower realized prices.
• Profitability: Net income rose 25% for the quarter and 72% for the six-month period. Gross margin expanded to 85.8% (Q2) and 84.0% (YTD) due to improved production costs and favorable product mix.
• Acquired IPR&D Charges: Significant increase in acquired in-process research and development (IPR&D) expenses to $2.8 billion (Q2) and $3.4 billion (YTD), compared to $154 million and $1.7 billion in the prior year periods. This was driven by acquisitions of Orna Therapeutics, Ajax Therapeutics, Kelonia, Centessa, and Ventyx.
• Special Charges: Asset impairment, restructuring, and other special charges totaled $703 million (Q2) and $982 million (YTD), primarily related to accelerated equity vesting and acquisition integration costs.
• Debt Levels: Total debt increased by $12.4 billion to $54.9 billion, reflecting new long-term debt issuances ($9.0 billion in May 2026) to fund acquisitions and general corporate purposes.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Product Pipeline: The FDA approved orforglipron (Foundayo) for obesity; submissions for type 2 diabetes are pending. Phase 3 trials for retatrutide (obesity and type 2 diabetes) met primary endpoints. Insulin efsitora alfa received a positive CHMP opinion in the EU.
• Pricing and Access: The company finalized drug pricing agreements with the U.S. government, including the Medicare GLP-1 Bridge Program effective July 1, 2026. The Inflation Reduction Act (IRA) price negotiations for Jardiance (effective 2026) and Trulicity/Verzenio (effective 2028) are noted as significant factors.
• Manufacturing: Significant manufacturing expansion initiatives are underway to support anticipated demand for incretin medicines.

Risks and Contingencies

• Legal Proceedings: Ongoing litigation includes patent disputes (Emgality, Verzenio, Tirzepatide), 340B pricing disputes, insulin pricing class actions, and product liability claims related to Mounjaro, Trulicity, and Zepbound (gastrointestinal and NAION injuries).
• Regulatory: Risks related to the IRA, global pricing pressures, and potential supply chain disruptions due to regulatory actions or manufacturing difficulties.
• Counterfeit Products: Continued production and sale of counterfeit and mass-compounded incretins pose patient safety and regulatory risks.

Investor Verification Checklist

• Revenue Sustainability: Verify the durability of volume growth for Mounjaro and Zepbound against the backdrop of lower realized prices and government pricing agreements (Medicare Bridge Program).
• Acquisition Integration: Assess the impact of $13.3 billion in business development spend and the associated $3.4 billion in IPR&D charges on future earnings and cash flow.
• Debt Servicing: Review the implications of the increased debt load ($54.9 billion) and interest rate exposure on future liquidity.
• Legal Exposure: Monitor the status of high-profile litigation, particularly the Emgality patent appeal, insulin pricing settlements, and product liability MDLs for incretin medicines.
• Regulatory Approvals: Track the approval timeline for orforglipron (Foundayo) for type 2 diabetes and the commercial uptake of new indications for retatrutide.